Moderna (MRNA) Receivables - Net (2017 - 2026)
Moderna (MRNA) posted quarterly Receivables - Net of $120.0 million for Q2 2026, down 53.85% year-over-year from $260.0 million in Q2 2025, and down 40.89% on a QoQ basis from $203.0 million in Q1 2026.
Moderna (MRNA) Receivables - Net (2017 - 2026) Analysis & Trends
Moderna has reported Receivables - Net for 10 years, with the latest figure at $120.0 million in Q2 2026.
- Receivables - Net for Q2 2026 came in at $120.0 million, down 53.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $120.0 million (down 53.85% YoY), and the FY2025 annual result was $368.0 million, down 47.28% from the prior year.
- Receivables - Net eased to $120.0 million in Q2 2026, from $203.0 million in the prior quarter.
- Over five years, Receivables - Net peaked at $3.2 billion in Q1 2022 and troughed at $120.0 million in Q2 2026.
- A 5-year average of $1.3 billion and a median of $905.5 million in 2023 frame the typical range for Receivables - Net.
- The widest annual swing landed in 2023, when Receivables - Net slumped 91.38%; it then soared 112.07% in 2024.
- A 5-year view of Receivables - Net shows it stood at $1.4 billion in 2022, then grew by 14.37% to $1.6 billion in 2023, then plunged by 55.93% to $698.0 million in 2024, then sank by 47.28% to $368.0 million in 2025, then sank by 67.39% to $120.0 million in 2026.
- Per Business Quant data, the three most recent Receivables - Net figures were $120.0 million in Q2 2026, $203.0 million in Q1 2026, and $368.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.00 Mn |
| Jun 30, 2026 | 120.00 Mn |
| Mar 31, 2026 | 203.00 Mn |
| Mar 31, 2026 | 203.00 Mn |
| Dec 31, 2025 | 368.00 Mn |
| Dec 31, 2025 | 368.00 Mn |
| Sep 30, 2025 | 2.02 Bn |
| Sep 30, 2025 | 2.02 Bn |
| Jun 30, 2025 | 61.00 Mn |
| Jun 30, 2025 | 61.00 Mn |
| Mar 31, 2025 | 249.00 Mn |
| Mar 31, 2025 | 249.00 Mn |
| Dec 31, 2024 | 698.00 Mn |
| Dec 31, 2024 | 698.00 Mn |
| Sep 30, 2024 | 2.73 Bn |
| Sep 30, 2024 | 2.73 Bn |
| Jun 30, 2024 | 163.00 Mn |
| Jun 30, 2024 | 163.00 Mn |
| Mar 31, 2024 | 422.00 Mn |
| Mar 31, 2024 | 422.00 Mn |